These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 35790883

  • 1. A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival.
    Shao MM, Qiao X, Chen QY, Yi FS.
    Thorac Cancer; 2022 Aug; 13(16):2318-2330. PubMed ID: 35790883
    [Abstract] [Full Text] [Related]

  • 2. Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.
    Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reynies A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D.
    Clin Cancer Res; 2017 Jun 15; 23(12):3191-3202. PubMed ID: 28003305
    [Abstract] [Full Text] [Related]

  • 3. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA, El-Din RS, Sabri NA, Abdel-Rahman CA, Bastawisy AE.
    Cancer Genet; 2018 Dec 15; 228-229():83-92. PubMed ID: 30553477
    [Abstract] [Full Text] [Related]

  • 4. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L.
    J Thorac Oncol; 2016 Jan 15; 11(1):94-107. PubMed ID: 26762744
    [Abstract] [Full Text] [Related]

  • 5. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K, Hiroshima K, Nagashima Y, Nakazawa T, Ogihara A, Orimo M, Sato Y, Katsura H, Kanzaki M, Kondo M, Tagaya E.
    BMC Cancer; 2023 Dec 07; 23(1):1206. PubMed ID: 38062416
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
    Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, de Koning L, Copin MC, Hofman P, Hofman V, Porte H, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, de Reyniès A, Jean D.
    Nat Commun; 2019 Mar 22; 10(1):1333. PubMed ID: 30902996
    [Abstract] [Full Text] [Related]

  • 11. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.
    Jiang Y, Zhang C, Chen Y, Zhao S, He Y, He J.
    Cancer Med; 2023 Feb 22; 12(4):4895-4906. PubMed ID: 36031798
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M, Yu M, Zhu LJ, Yuan XY, Zhang X.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb 20; 39(2):91-98. PubMed ID: 33691361
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG, Salinas-Silva LC, Vázquez-Manríquez ME, Gayosso-Gómez LV, Negrete-Garcia MC, Ramírez-Rodriguez SL, Chávez R, Zenteno E, Santillán P, Kelly-García J, Ortiz-Quintero B.
    Exp Mol Pathol; 2014 Dec 20; 97(3):375-85. PubMed ID: 25236577
    [Abstract] [Full Text] [Related]

  • 16. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
    Dong L, Jensen RV, De Rienzo A, Gordon GJ, Xu Y, Sugarbaker DJ, Bueno R.
    BMC Med Genet; 2009 Dec 31; 10():149. PubMed ID: 20043850
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Shukuya T, Oyanagi J, Serizawa M, Watanabe M, Yamamoto N, Koh Y.
    Anticancer Res; 2020 Apr 31; 40(4):1867-1874. PubMed ID: 32234874
    [Abstract] [Full Text] [Related]

  • 18. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M, Atay SM, Shukla V, Hong Y, Upham T, Ripley RT, Hong JA, Zhang M, Reardon E, Fetsch P, Miettinen M, Li X, Peer CJ, Sissung T, Figg WD, De Rienzo A, Bueno R, Schrump DS.
    Clin Cancer Res; 2016 Mar 01; 22(5):1197-210. PubMed ID: 26459178
    [Abstract] [Full Text] [Related]

  • 19. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.
    J Pathol; 2015 Oct 01; 237(2):203-14. PubMed ID: 26011651
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.